1613081-64-3
Chemical Structure
Ruzasvir
Synonym(s): MK-8408
- CAS No.: 1613081-64-3
- Formula:C49H55FN10O7S
- Molecular Weight:947.09
IUPAC Name: dimethyl ((2S,2'S)-((2S,2'S)-(((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate
InChIKey: AXWDHVUJXNOWCC-RAEGKSCOSA-N
SMILES: FC1=C2C3=CC4=CC(C5=CN=C([C@H](CCC6)N6C([C@H](C(C)C)NC(OC)=O)=O)N5)=CC=C4N3[C@H](C7=CN=C(C8CC8)S7)OC2=CC(C9=CN=C([C@H](CCC%10)N%10C([C@H](C(C)C)NC(OC)=O)=O)N9)=C1
Biological Activity: Ruzasvir (MK-8408) is a potent, pan-genotype HCV NS5A inhibitor that blocks RNA synthesis, replication, and assembly. Ruzasvir produces additive to synergistic antiviral effects with Bemnifosbuvir (HY-137958A), Grazoprevir (HY-15298), or Uprifosbuvir (HY-103487) analogs, with no antagonism. Ruzasvir can be used for research on HCV infection[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ruzasvir | 98.15% | Ruzasvir (MK-8408) is a potent, pan-genotype HCV NS5A inhibitor that blocks RNA synthesis, replication, and assembly. Ruzasvir produces additive to synergistic antiviral effects with Bemnifosbuvir (HY-137958A), Grazoprevir (HY-15298), or Uprifosbuvir (HY-103487) analogs, with no antagonism. Ruzasvir can be used for research on HCV infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gottwein JM, et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants. Gastroenterology. 2018 Apr 1;154(5):1435-48.
- [2]. Chan A, et al. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017 Feb;77(2):131-144.
- [3]. Tong L, et al. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. Journal of medicinal chemistry. 2017 Jan 12;60(1):290-306. [Content Brief]
- [4]. Hu J, et al. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. Gut. 2026 Mar 06.
- [5]. Good SS, et al. Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo. Antiviral research. 2025 May;237:106137.
- [6]. Asante-Appiah E, et al. Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrobial agents and chemotherapy. 2018 Nov;62(11):e01280-18.
- [7]. Tong L, et al. Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections. InComplete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1 2018 (pp. 115-149). American Chemical Society.
